The Duke Center for Advanced Genomic Technologies will investigate and re-engineer cellular gene regulation machinery and networks to help discover new drug targets and gene therapies to fight diseases including neurodegenerative, autoimmune, cardiovascular disorders and predisposition to cancer.
While CAGT will focus its research efforts on the human genome, the center aims to specifically address the so-called “dark genome,” which is a vast and largely unexplored area of non-protein-coding DNA believed to harness information to treat complex disorders such as cancer and neurological disease. The dark genome holds genetic regulators responsible for more than 90 percent of susceptibility to common diseases, according to the news release.
CAGT will focus its research efforts on five key areas: genome structure and function, gene regulation, epigenomics of disease, genomics of drug response and genome engineering technologies.
More articles on innovation:
USC to offer minor in health innovation in spring 2020
Washington State U to open innovation complex with virtual hospital, research accelerator
Ajax Health launches 3rd $100M innovation venture fund
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
